None listed
Conditions
Interventions
Intervention1: Thiamine: 300 mg per day
Control Intervention1: Placebo:
Sponsors
Sheikh Zayed Hospital Lahore Pakistan
Eligibility
Inclusion criteria
Inclusion criteria: Age 35-65 years old, Patients with type 2 diabetes and microalbuminuria (albumin excretion rate (AER) 30 - 299 mg/24 h), Diabetes duration of 5 years or more, Glycated haemoglobin HbA1c ≤12.5%, Body mass index (BMI) 19 - 40 kg/m2.
Exclusion criteria
Exclusion criteria: Allergy or intolerance to thiamine, Participation in another clinical study within the last 30 days, Women who are pregnant or breast feeding, Women of child bearing potential not using adequate contraceptive precautions, End stage renal disease (creatinine > 2mg/dl), Liver diseases (ASTP >3xULN, serum albumin <3.4 g/dl, acute hepatitis), and Any other significant morbidity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary excertion of albumin (24 h collection)Timepoint: Baseline; after 1, 2 and 3 months therapy; and after 1 and 2 months washout. | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma cholesterol and triglyceridesTimepoint: Baseline; after 1, 2 and 3 months therapy; and after 1 and 2 months washout. | — |
Countries
Pakistan
Contacts
Public ContactDr Naila Rabbani
University of Warwick (UK)
Outcome results
None listed